IL-6R (trans-signaling) is a key regulator of reverse cholesterol transport in lipid-laden macrophages
Clinical Immunology · 2024
DOI: 10.1016/j.clim.2024.110351 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2024. Verfasst von Fatema Al-Rashed und 5 weiteren Autor:innen. Beteiligte Einrichtung: Immunology and Microbiology Department, Dasman Diabetes Institute, Al-Soor Street, Dasman, Kuwait, PO BOX 1180, Dasman 15462, Kuwait. Electronic addr…. Hauptthemen laut MEDLINE: Atherosclerosis, Cholesterol, Cytokine Receptor gp130, Macrophages. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Kuwait Foundation for the Advancement of Sciences.
Abstract (Originalsprache)
Atherosclerosis is a cardiovascular disease caused by cholesterol-laden arterial plaques. This study evaluated the correlation between interleukin-6 (IL-6), its receptors (IL6R/CD126), and glycoprotein 130 (gp130) alongside atherosclerosis biomarkers in a cohort of 142 subjects, equally divided between lean and obese individuals. Subsequent analyses used THP-1-derived macrophages to assess the biochemical impact of inhibiting IL-6 receptors. IL-6 secretion increased with atherosclerosis in obese subjects, while IL6R/CD126 and gp130 on monocytes decreased. Pharmacological gp130 inhibition altered lipid metabolism, increasing LDLR gene expression and cholesterol synthesis via SREBF2 and mevalonate kinase, along with HMG-CoA reductase at protein levels. gp130-deficient cells produced more cholesterol and had lower ABCA1 levels, suggesting hindered cholesterol efflux. Filipin III staining confirmed cholesterol retention in gp130-inhibited cells. Ex-vivo investigation on lean PBMCs further defined the impact of gp130 inhibition on the reduction of cholesterol efflux. Our results indicates gp130 is crucial for macrophage reverse cholesterol transport and may be a target for atherosclerosis treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology and Microbiology Department, Dasman Diabetes Institute, Al-Soor Street, Dasman, Kuwait, PO BOX 1180, Dasman 15462, Kuwait. Electronic address: fatema.alrashed@dasmaninstitute.org.
- Immunology and Microbiology Department, Dasman Diabetes Institute, Al-Soor Street, Dasman, Kuwait, PO BOX 1180, Dasman 15462, Kuwait.
- Genetics and Bioinformatics Department, Dasman Diabetes Institute, Kuwait, Kuwait.
- Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- Kuwait Foundation for the Advancement of Sciences
- National Institutes of Health
Zitieren
APA
Al-Rashed, F., AlSaeed, H., Almansour, N., Al-Mulla, F., Hannun, Y. A., & Ahmad, R. (2024). IL-6R (trans-signaling) is a key regulator of reverse cholesterol transport in lipid-laden macrophages. Clinical Immunology. https://doi.org/10.1016/j.clim.2024.110351
Vancouver
Al-Rashed F, AlSaeed H, Almansour N, Al-Mulla F, Hannun YA, Ahmad R. IL-6R (trans-signaling) is a key regulator of reverse cholesterol transport in lipid-laden macrophages. Clinical Immunology. 2024. doi:10.1016/j.clim.2024.110351
BibTeX
@article{AlRashed2024,
author = {Al-Rashed, Fatema and AlSaeed, Halemah and Almansour, Nourah and Al-Mulla, Fahd and Hannun, Yusuf A and Ahmad, Rasheed},
title = {IL-6R (trans-signaling) is a key regulator of reverse cholesterol transport in lipid-laden macrophages},
journal = {Clinical Immunology},
year = {2024},
doi = {10.1016/j.clim.2024.110351}
}
EUVIMED